Search Results
Showing Results for macular neovascularization
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...
The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part ...
Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...
Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1Â They have established themselves as the primary approach for administering anti-vascular ...
Age-related macular degeneration (AMD) is a progressive eye condition that affects millions of people worldwide and poses a significant threat to vision in individuals over the age of 50.1Â Of the two types of AMD, wet AMD, which is characterized by ...
Article highlights Artificial intelligence (AI) represents a powerful way of analysing a large amount of data, extracting those features characterizing a given disease or condition. AI-based models have been largely tested in the main retinopathies, including age-related macular degeneration, diabetic ...
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous ...
Identifying treatments that prevent diabetic retinopathy progression is a priority in current research. Patients with non-proliferative retinopathy currently have limited treatment options to prevent the progression of retinopathy and loss of vision, and therapies such as anti-vascular endothelial growth factor (...
Welcome to the winter edition of touchREVIEWS in Ophthalmology, which features relevant topics from across the specialty. This edition contains a wide range of articles evaluating current practice and research, as well as innovations that directly affect ophthalmologists. The surgical ...
The subspecialty of the retina has been transformed by anti-vascular endothelial growth factor (anti-VEGF) medications over the last two decades.1 These include bevacizumab (Avastin®, Genetech, San Francisco, CA, USA), ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA), aflibercept (Eylea®, Regeneron Pharmaceuticals, ...
Type 1 neovascularization can be a secondary feature of central serous chorioretinopathy. In this touchOPHTHALMOLOGY interview, Dr Dinah Zur (Center for Retinal Degenerations, Ophthalmology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel) talks us through the implications of improper diagnosis of this ...
Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) associated with macular oedema are some of the leading causes of visual impairment and loss worldwide.1–3 The pathogenesis of these diseases is largely driven by the ...
Age-related macular degeneration (AMD) is a leading cause of vision impairment and legal blindness in developed countries, with a projected estimate of 288 million cases in 2040.1Â AMD can be classified as exudative or non-exudative. The early AMD-related lesion is represented by ...
Combined cataract-vitreoretinal surgery (also known as phacovitrectomy) consists of pars plana vitrectomy (PPV), phacoemulsification and implantation of an intraocular lens (IOL). Phacovitrectomy can be performed by a single vitreoretinal surgeon or by an anterior segment surgeon working in tandem with ...
Age-related macular degeneration (AMD) is characterized by age-associated thinning of the macula and formation of drusen. It has substantial global prevalence, especially in the older population, and it is the primary cause of permanent loss of vision in individuals 50 years ...
The development of anti-vascular endothelial growth factor (VEGF) agents as intravitreal treatments for neovascular age-related macular degeneration (nAMD) has drastically improved the vision outcomes for this disorder. Ranibizumab, a recombinant, humanized monoclonal antibody that targets VEGF-A, was approved in 2006 by ...
Neovascular age-related macular degeneration (nAMD) is characterized by the growth of abnormal blood vessels extending through Bruchs membrane in the macular region.1 This macular neovascularization (MNV) can be classified based on localization as either type 1, type 2, type 3 or mixed lesions.2 ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
